webinar register page

Fireside Chat: VBI Vaccines hosted by Steve Seedhouse

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel, under the name Sci-B-Vac®, and recently completed its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and two prophylactic coronavirus vaccine candidates. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Management Team:
Jeff Baxter – President & Chief Executive Officer
David Anderson, Ph.D – Chief Scientific Officer

Hosted by Steve Seedhouse, Steve.Seedhouse@RaymondJames.com | Biotech


*Upon registration you’ll receive a confirmation email with your dial-in details. Please add to your Outlook calendar for easy access to the call.

Dec 8, 2020 08:00 AM in Pacific Time (US and Canada)